Showing results (1821-1830 of 1,899) with videos related to
Sort By:
Pageof 190
Immunotherapy|July 23, 2024
Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutationAnna Babayan, Evgeny Ledin, Alexandra Lebedeva, et al.Immunotherapy|June 18, 2024
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapyKaterina Kampoli, Ioannis Tsamis, Dimitrios Sgouros, et al.Immunotherapy|September 6, 2023
Tackling the immunotherapy conundrum: advances and challenges for operable non-small-cell lung cancer treatmentFouad Attieh, Antoine Chartouni, Marc Boutros, et al.Immunotherapy|September 7, 2023
The role of upadacitinib for the treatment of axial spondyloarthritisNavya George, Jean W Liew, Maureen DubreuilImmunotherapy|August 23, 2023
Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septenniumElena Carmona-Rocha, Lluís PuigImmunotherapy|August 17, 2023
Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in ThailandAjanee Mahakkanukrauh, Sumapa Chaiamnuay, Ajchara Koolvisoot, et al.Immunotherapy|August 16, 2023
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAsHamideh Bashiri, Maryam Moazam-Jazi, Mohammad Reza Karimzadeh, et al.Immunotherapy|January 10, 2024
Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinomaFang Yan, Longpei Chen, Mingzhen Ying, et al.Immunotherapy|January 10, 2024
SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanomaXuan Wang, Hongming Pan, Jiuwei Cui, et al.Immunotherapy|January 10, 2024
A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trialsTulay Kus, Irfan CicinPageof 190